NCT06924697Csak meghívásos
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients: Study Protocol of a Randomized, Parallel -Controlled Clinical Trial
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. máj. 31. · Több mint 12 hónapja nem frissült - kérdezd meg a helyszínt, nyitott-e még
Rövid összefoglaló (regiszter, angolul)
Diabetes has become an increasingly serious global health issue. In 2024, approximately 537 million adults were living with diabetes, and this number is projected to rise to 783 million by 2045, representing a 46% increase. Against the backdrop of a growing global diabetes epidemic, smoking among individuals with diabetes poses a significant threat, further exacerbating clinical and public health burdens. Despite over 50 years of tobacco control efforts, smoking remains one of the greatest public health threats in history, causing more than 8 million deaths annually worldwide. Among these, over 7 million deaths result from direct tobacco use, while approximately 1.3 million deaths are attributed to secondhand smoke exposure. Recent studies have shown that smoking increases the risk of developing prediabetes and diabetes. Moreover, individuals with diabetes who smoke have a higher risk of all-cause mortality, worsened chronic diabetic complications, an increased likelihood of developing cancer and cardiovascular diseases, and greater difficulty in glycemic control. Despite substantial evidence highlighting the detrimental effects of smoking on individuals with diabetes, national surveys from the 1990s indicated similar smoking prevalence rates between individuals with and without diabetes (27.3% and 25.9%, respectively). Although various smoking cessation methods are available, the success rate of quitting remains low, necessitating novel intervention strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes. They exert hypoglycemic effects by stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon secretion, enhancing glucose uptake in muscle and adipose tissue, suppressing hepatic glucose production, delaying gastric emptying, and reducing appetite. Existing studies suggest that GLP-1 influences the brain's reward system, and GLP-1RAs have been shown to reduce nicotine dependence in animal models. Recent clinical research has demonstrated that GLP-1RAs can be used in combination with nicotine patches to facilitate smoking cessation. However, whether GLP-1RAs alone can directly promote smoking cessation in individuals with diabetes remains unclear. Therefore, this study aims to investigate the potential direct effects of GLP-1RAs on smoking cessation in patients with type 2 diabetes.
- Állapot (regiszter)
- Csak meghívásos
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 46 (tervezett)
- Első benyújtás
- 2025. márc. 16.
- Kezdés
- 2025. jún. 21.
- Elsődleges befejezés
- 2026. jan. 11.
- Fő szponzor
- Shanghai East Hospital
- Betegségek
- 2-es típusú cukorbetegség
- NCT-szám
- NCT06924697
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 46
- 2025. jún. 21. és az elsődleges befejezés (2026. jan. 11.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Contraindications to magnetic resonance imaging (MRI), such as metallic implants, pacemakers, or claustrophobia.
- -
Más betegség
- Diagnosis of type 1 diabetes or other specific types of diabetes.
- Patients with severe cardiovascular, hepatic, renal, neurological, immune, or hematological diseases.
- Presence of severe infections, malignancies, recent surgeries, or major trauma.
- A history of severe recurrent hypoglycemia.
- Severe gastrointestinal disorders, such as gastroparesis.
- A history of pancreatitis or a high risk of developing pancreatitis.
- Presence of severe psychiatric disorders, including schizophrenia, paranoid psychosis, bipolar disorder, or intellectual disability.
Egyéb
- Presence of diabetic ketoacidosis or severe diabetic complications.
- Poor adherence or inability to attend scheduled follow-up visits.
Kiket keres a vizsgálat
- Male patients aged 18-75 years.
- Diagnosis of type 2 diabetes mellitus (T2DM) based on the World Health Organization (WHO) criteria.
- A history of smoking for at least one year.
- Fagerström Test for Nicotine Dependence (FTND) score ≥4.
- Eligible for treatment with glucagon-like peptide-1 receptor agonists (GLP1-RAs) or dipeptidyl peptidase-IV (DPP-IV) inhibitors but have not previously used these medications.
- Patients who fully understand the study, voluntarily participate, and sign the informed consent form.
Életkor a regiszterben: 18 év – 75 év · Nem: csak férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Department of Endocrinology, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Shanghai | Shanghai | Kína | Ismeretlen állapot |
Kapcsolódó publikációk
- Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial.Front Clin Diabetes Healthc · 2026 · PMID 41704542
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.